Palvella Therapeutics, Inc. Depreciation
Palvella Therapeutics, Inc. (PVLA) reported Depreciation of $1.80 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-29.
Discontinued › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2024-03-29
- Palvella Therapeutics, Inc. depreciation for the quarter ending 2020-06-30 was $530.00K, a 1161.90% increase year-over-year.
- Palvella Therapeutics, Inc. depreciation for the quarter ending 2020-03-31 was $339.00K, a 104.22% increase year-over-year.
- Palvella Therapeutics, Inc. depreciation for the quarter ending 2019-12-31 was $233.00K, a 41.21% increase year-over-year.
- Palvella Therapeutics, Inc. depreciation for the quarter ending 2019-09-30 was $159.00K, a 22.31% increase year-over-year.
- Palvella Therapeutics, Inc. depreciation for fiscal 2023 was $1.80M, a 21.74% decline from fiscal 2022.
- Palvella Therapeutics, Inc. depreciation for fiscal 2022 was $2.30M, a 4.17% decline from fiscal 2021.
- Palvella Therapeutics, Inc. depreciation for fiscal 2021 was $2.40M, a 14.29% increase from fiscal 2020.
- Palvella Therapeutics, Inc. depreciation for fiscal 2020 was $2.10M, a 250.00% increase from fiscal 2019.
| Period end | Depreciation 3 month | Depreciation 3 month as first filed | Depreciation 6 month | Depreciation 6 month as first filed | Depreciation 9 month | Depreciation 9 month as first filed | Depreciation 12 month | Depreciation 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2023-12-31 | $1.80M 10-K · filed 2024-03-29 | |||||||
| 2022-12-31 | $2.30M 10-K · filed 2024-03-29 | |||||||
| 2021-12-31 | $2.40M 10-K · filed 2023-03-31 | |||||||
| 2020-12-31 | $2.10M 10-K · filed 2022-03-02 | |||||||
| 2020-06-30 | $530.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $869.00K 10-Q · filed 2020-08-10 | $1.10M derived: sum of 3 quarters · filed 2021-03-31 | $1.26M derived: sum of 4 quarters · filed 2021-03-31 | ||||
| 2020-03-31 | $339.00K 10-Q · filed 2020-05-11 | $572.00K derived: sum of 2 quarters · filed 2021-03-31 | $731.00K derived: sum of 3 quarters · filed 2021-03-31 | $773.00K derived: sum of 4 quarters · filed 2021-03-31 | ||||
| 2019-12-31 | $233.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | $392.00K derived: sum of 2 quarters · filed 2021-03-31 | $434.00K derived: sum of 3 quarters · filed 2021-03-31 | $600.00K 10-K · filed 2021-03-31 | $632.00K 10-K · filed 2020-03-13 | |||
| 2019-09-30 | $159.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | $201.00K derived: sum of 2 quarters · filed 2020-11-04 | $367.00K 10-Q · filed 2020-11-04 | $532.00K derived: sum of 4 quarters · filed 2020-11-04 | ||||
| 2019-06-30 | $42.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $208.00K 10-Q · filed 2020-08-10 | $373.00K derived: sum of 3 quarters · filed 2020-08-10 | $503.00K derived: sum of 4 quarters · filed 2020-08-10 | ||||
| 2019-03-31 | $166.00K 10-Q · filed 2020-05-11 | $331.00K derived: sum of 2 quarters · filed 2020-05-11 | $461.00K derived: sum of 3 quarters · filed 2020-05-11 | $602.00K derived: sum of 4 quarters · filed 2020-05-11 | ||||
| 2018-12-31 | $165.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-13 | $295.00K derived: sum of 2 quarters · filed 2020-03-13 | $436.00K derived: sum of 3 quarters · filed 2020-03-13 | $570.00K 10-K · filed 2020-03-13 | ||||
| 2018-09-30 | $130.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $271.00K derived: sum of 2 quarters · filed 2019-11-12 | $405.00K 10-Q · filed 2019-11-12 | $506.00K derived: sum of 4 quarters · filed 2019-11-12 | ||||
| 2018-06-30 | $141.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | $275.00K 10-Q · filed 2019-08-09 | $376.00K derived: sum of 3 quarters · filed 2019-08-09 | $431.00K derived: sum of 4 quarters · filed 2019-08-09 | ||||
| 2018-03-31 | $134.00K 10-Q · filed 2019-05-10 | $235.00K derived: sum of 2 quarters · filed 2019-05-10 | $290.00K derived: sum of 3 quarters · filed 2019-05-10 | $403.00K derived: sum of 4 quarters · filed 2019-05-10 | ||||
| 2017-12-31 | $101.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-18 | $156.00K derived: sum of 2 quarters · filed 2019-03-18 | $269.00K derived: sum of 3 quarters · filed 2019-03-18 | $369.00K 10-K · filed 2019-03-18 | ||||
| 2017-09-30 | $55.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $168.00K derived: sum of 2 quarters · filed 2018-11-07 | $268.00K 10-Q · filed 2018-11-07 | $268.21K 10-Q · filed 2017-11-13 | $453.61K derived: sum of 4 quarters · filed 2018-11-07 | |||
| 2017-06-30 | $113.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $213.00K 10-Q · filed 2018-08-09 | $213.38K 10-Q · filed 2017-08-11 | $398.61K derived: sum of 3 quarters · filed 2018-08-09 | $491.24K derived: sum of 4 quarters · filed 2018-08-09 | |||
| 2017-03-31 | $100.00K 10-Q · filed 2018-05-10 | $100.35K 10-Q · filed 2017-05-15 | $285.61K derived: sum of 2 quarters · filed 2018-05-10 | $378.24K derived: sum of 3 quarters · filed 2018-05-10 | $366.48K derived: sum of 4 quarters · filed 2018-05-10 | |||
| 2016-12-31 | $185.61K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15 | $278.24K derived: sum of 2 quarters · filed 2018-03-15 | $266.48K derived: sum of 3 quarters · filed 2018-03-15 | $361.00K 10-K · filed 2018-03-15 | $361.38K 10-K · filed 2017-03-30 | |||
| 2016-09-30 | $92.63K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-13 | $80.87K derived: sum of 2 quarters · filed 2017-11-13 | $175.39K 10-Q · filed 2017-11-13 | $249.23K derived: sum of 4 quarters · filed 2017-11-13 | ||||
| 2016-06-30 | -$11.76K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-11 | $82.76K 10-Q · filed 2017-08-11 | $156.60K derived: sum of 3 quarters · filed 2017-08-11 | $236.11K derived: sum of 4 quarters · filed 2017-08-11 | ||||
| 2016-03-31 | $94.52K 10-Q · filed 2017-05-15 | $168.36K derived: sum of 2 quarters · filed 2017-05-15 | $247.87K derived: sum of 3 quarters · filed 2017-05-15 | $324.31K derived: sum of 4 quarters · filed 2017-05-15 | ||||
| 2015-12-31 | $73.84K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-30 | $153.35K derived: sum of 2 quarters · filed 2017-03-30 | $229.79K derived: sum of 3 quarters · filed 2017-03-30 | $307.91K 10-K · filed 2017-03-30 | ||||
| 2015-09-30 | $79.51K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-10 | $155.95K derived: sum of 2 quarters · filed 2016-11-10 | $234.07K 10-Q · filed 2016-11-10 | $322.19K derived: sum of 4 quarters · filed 2016-11-10 | ||||
| 2015-06-30 | $76.44K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-11 | $154.56K 10-Q · filed 2016-08-11 | $242.68K derived: sum of 3 quarters · filed 2016-08-11 | $332.07K derived: sum of 4 quarters · filed 2016-08-11 | ||||
| 2015-03-31 | $78.12K 10-Q · filed 2016-05-12 | $166.24K derived: sum of 2 quarters · filed 2016-05-12 | $255.63K derived: sum of 3 quarters · filed 2016-05-12 | $349.55K derived: sum of 4 quarters · filed 2016-05-12 | ||||
| 2014-12-31 | $88.13K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-23 | $177.52K derived: sum of 2 quarters · filed 2016-03-23 | $271.43K derived: sum of 3 quarters · filed 2016-03-23 | $366.98K 10-K · filed 2016-03-23 | ||||
| 2014-09-30 | $89.39K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-13 | $183.30K derived: sum of 2 quarters · filed 2015-11-13 | $278.85K 10-Q · filed 2015-11-13 | |||||
| 2014-06-30 | $93.91K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-13 | $189.46K 10-Q · filed 2015-08-13 | ||||||
| 2014-03-31 | $95.55K 10-Q · filed 2015-05-14 | |||||||
| 2013-12-31 | $384.68K 10-K · filed 2015-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |